Document Detail

Diverse spectrum of presentation of coronary slow flow phenomenon: a concise review of the literature.
Jump to Full Text
MedLine Citation:
PMID:  22645695     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The coronary slow flow phenomenon (CSFP) is a disease entity characterized by slow progression of angiographic contrast in the coronary arteries in the absence of stenosis in the epicardial vessels. CSFP has a diverse presentation from mild chest discomfort to ST-segment elevation myocardial infarction. It can also have severe morbidity and mortality implications and can significantly hamper the quality of life of those affected. In this paper we present two patients with CSFP highlighting the diverse spectrum of presentation. A concise review of the literature is also provided emphasizing the epidemiology, pathogenesis, diagnostic parameters, treatment modalities, and clinical significance of this phenomenon.
Authors:
Muhammad A Chaudhry; Marcus Smith; Elias B Hanna; Ralph Lazzara
Related Documents :
8374945 - Severe diffuse intracranial vasospasm as a cause of extensive migrainous cerebral infar...
18836265 - Frequency and clinical significance of acute bilateral cerebellar infarcts.
21633575 - Pediatric cardiac emergencies: children are not small adults.
1529945 - Prevalence of anticardiolipin antibody in isolated mitral or aortic regurgitation, or b...
22496085 - Effect of iron chelation on myocardial infarct size and oxidative stress in st-elevatio...
7934115 - Prolonged neonatal myocardial preservation with a highly buffered low-calcium solution.
Publication Detail:
Type:  Journal Article     Date:  2012-05-08
Journal Detail:
Title:  Cardiology research and practice     Volume:  2012     ISSN:  2090-0597     ISO Abbreviation:  Cardiol Res Pract     Publication Date:  2012  
Date Detail:
Created Date:  2012-05-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101516542     Medline TA:  Cardiol Res Pract     Country:  United States    
Other Details:
Languages:  eng     Pagination:  383181     Citation Subset:  -    
Affiliation:
Section of Cardiology, Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126-0901, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Cardiol Res Pract
Journal ID (iso-abbrev): Cardiol Res Pract
Journal ID (publisher-id): CRP
ISSN: 2090-8016
ISSN: 2090-0597
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2012 Muhammad A. Chaudhry et al.
open-access:
Received Day: 27 Month: 10 Year: 2011
Revision Received Day: 19 Month: 2 Year: 2012
Accepted Day: 20 Month: 2 Year: 2012
Print publication date: Year: 2012
Electronic publication date: Day: 8 Month: 5 Year: 2012
Volume: 2012E-location ID: 383181
ID: 3356868
PubMed Id: 22645695
DOI: 10.1155/2012/383181

Diverse Spectrum of Presentation of Coronary Slow Flow Phenomenon: A Concise Review of the Literature
Muhammad A. Chaudhry1*
Marcus Smith1
Elias B. Hanna2
Ralph Lazzara1
1Section of Cardiology, Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126-0901, USA
2Cardiovascular Section, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
Correspondence: *Muhammad A. Chaudhry: muhammad-chaudhry@ouhsc.edu
[other] Academic Editor: Michael S. Wolin

1. Case Presentations
1.1. Patient 1

The first case involved a 43-year-old man with a past medical history of hyperlipidemia and hypertension who presented to the hospital with chest pain. The chest pain was described as a pressure-like sensation in the center of his chest, 8/10 in severity, and radiated down his left arm. Upon presentation, vital signs were stable, cardiac biomarkers were within normal limits, and the electrocardiogram (EKG) showed no ST/T-waves changes. Transthoracic echocardiogram showed normal left ventricle function and no wall motion abnormalities. Of note, the patient had a similar presentation and ER course two weeks prior.

Due to the fact that the patient continued to have 8/10 chest pain during his hospital stay, coronary angiogram was ultimately done. The angiogram showed normal coronary arteries without evidence of coronary vasospasm or an existing myocardial bridge. Slow flow, however, was noted in the left anterior descending artery (LAD). An intracoronary adenosine challenge was done and showed normalization of the TIMI (Thrombolysis in Myocardial Infarction) frame count (Figure 1). The patient was given the diagnosis of coronary slow flow phenomenon and started on dipyridamole 50 mg three times a day and discharged home.

On six-month followup, the patient reported that he had been chest-pain-free. Shortly after his six-month followup, the patient ran out of his medicine and again began to experience chest pain. Once the patient was placed back on his dipyridamole, he became chest-pain-free.

1.2. Patient 2

The second case involved a 70-year-old gentleman with a past medical history of squamous cell carcinoma of the base of tongue six years prior. The patient presented with a single episode of chest pain at rest described as pressure-like and associated with shortness of breath and diaphoresis. Admission EKG revealed T-wave inversion in the anterior leads and a prolonged QT interval (Figure 2). Cardiac enzymes were also noted to be elevated (CKMB 8.3 IU/l and troponin I 1.14 ng/mL). Transthoracic echocardiogram showed normal left ventricular function with no wall motion abnormalities or left ventricular hypertrophy. A diagnosis of non-ST-elevation myocardial infarction (NSTEMI) was made, and the patient was started on the appropriate acute coronary syndrome medications. Left heart catheterization was done the following day and revealed normal coronary arteries with slow flow noted in LAD. An intracoronary adenosine challenge was done that showed normalization of the TIMI frame count (Figure 3). The patient was given the diagnosis of coronary slow flow and started on amlodipine 2.5 mg daily. On 6-month followup, the patient reports that he has been chest-pain-free.


2. Introduction

CSFP was first described by Tambe et al. in 1972, and is defined as delayed opacification of coronary vessels during angiography without any evident obstructive disease [1]. Quantitatively, it is measured as increased Thrombolysis in Myocardial Infarction (TIMI) frame count. TIMI frame count, introduced by Gibson, is a reproducible index of coronary flow and represents the number of cine frames required for contrast to reach a prespecified distal coronary artery landmark. TIMI frame count is further corrected in the left anterior descending artery (LAD) by normalizing for the LAD length. The corrected TIMI frame count (CTFC) divides the absolute TIMI frame count in the LAD by 1.7. CSFP is defined as CTFC > 2 standard deviations from normal published range (21 ± 3) [2].


3. Presentation

The presentation of this phenomenon is extremely diverse ranging from stable or unstable angina, non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), nonsustained ventricular tachycardia (NSVT), and even vague chest discomfort. Yilmaz et al. found in their study that patients with CSFP had higher total cholesterol level (including higher low-density lipoprotein levels), higher body mass index, and a higher prevalence of metabolic syndrome [3]. Azzarelli et al. showed in a case series that patients with CSFP often present with recurrent chest pain [4]. New onset intermittent left bundle branch block (LBBB) has also been reported in association with CSFP in a patient presenting with acute coronary syndrome [5].


4. Incidence

The overall incidence of CSFP is 1% among patients who undergo coronary angiography, especially those presenting with acute coronary syndrome [6]. In TIMI-IIIA study, the incidence of CSFP was 4% among patients who presented with unstable angina and had none or insignificant epicardial coronary artery disease [7].


5. Pathogenesis

The pathogenesis of CSFP is still not well understood. There are some typical histopathological features associated with CSFP based on which reduction of luminal diameter and functional obstruction are believed to be the key events in its pathogenesis. Mosseri et al. demonstrated medial hypertrophy, myointimal proliferation, and endothelial degeneration along with changes of myofibrillar degenerative foci with lipofuscin deposits at electron microscopic level [8]. Luminal narrowing was attributed to endothelial swelling and degeneration. Mangieri et al. substantiated these findings in CSFP patients by showing small vessel thickening with associated luminal narrowing, dilated interstitial spaces filled with granular fibrillar material, decreased intracellular glycogen, distorted mitochondrial cristae, and patchy myofibrillar disarray at electron microscopic level [9]. Based on this, it was suggested that fibromuscular hyperplasia and medial hypertrophy with consequent decrease in luminal diameter lead to functional obstruction and CSFP.

The occurrence of CSFP is also believed to be strongly associated with elevated homocysteine levels which cause significant injury and consequent endothelial impairment [10]. Endothelial damage secondary to decreased nitric oxide levels, with elevated levels of nitric oxide synthase inhibitor and asymmetric dimethyl arginine (ADMA) are also considered as chief contributory factors [11, 12]. The basic underlying event is endothelial injury which leads to functional obstruction and disease manifestation.

Aortic pulse pressure and pulsatility index was found to be significantly elevated in patients with CSFP. It is believed that this could possibly be caused by endothelial dysfunction in CSFP. Increased aortic stiffness in CSFP was shown by Tanriverdi et al. in a study of 154 patients which included 81 patients with angiographically proven CSFP and 73 patients with normal coronary flow [13].

Impaired coronary flow reserve is another important feature in CSFP which is related to increased resting coronary microvascular tone. With increased myocardial oxygen demand, the inability to maximize coronary flow can reflect as persistent and recurrent chest pain in CSFP. In a study by Erdogan et al. which included 20 patients with CSFP and 15 controls, coronary flow reserve was significantly reduced in the CSFP group [18]. This was also shown by Mangieri et al. in a study of twenty-eight patients with CSFP in which 14 patients had coronary slow flow in one vessel and 14 had coronary slow flow in three vessels. After dipyridamole infusion, coronary angiography was done and single photon emission computed tomography (SPECT) scan was performed. Interestingly, TIMI frame count decreased after dipyridamole infusion in both groups while SPECT score increased in the first group and was reduced in the second group [19]. This suggests that myocardial perfusion in more extensive CSFP is significantly impaired and reflects the poor coronary flow reserve in these patients. A list of characteristic disease associations of CSFP is outlined in Table 1.


6. Treatment

The treatment for CSFP is still a matter of debate and a number of drugs have shown variable benefits. Simvastatin has shown to improve myocardial perfusion in patients with CSFP [20]. The pleiotropic effect, direct endothelial function effect, and the antithrombotic and anti-inflammatory actions of statins appear to be responsible for this improved perfusion [21]. In a study by Fan et al. which included 91 patients with CSFP, significant improvement in coronary flow reserve was shown after treatment with atorvastatin 20 mg daily for eight weeks [22]. This study highlights the importance of statin therapy in treatment of CSFP.

Nebivolol has also shown to be effective at improving endothelial function in patients with CSFP. It controls chest pain, decreases C reactive protein (CRP), and significantly improves coronary flow [23].

Dipyridamole, which has a vasodilator effect on the coronary microvasculature, is being used as treatment for CSFP as well. In a study where 25 patients with CSFP were administered dipyridamole 75 mg three times a day for one month, coronary flow returned to normal in 70 out of 75 vessels. Typical angina complaints resolved in 17 patients (68%), and decreased in frequency in the remaining 8 patients (32%) [24]. Dipyridamole abolishes functional obstruction in coronary arteries with diameters less than 200 micrometers and is considered far superior in treating CSFP as compared to nitroglycerine [24].

There is no substantial data regarding the use of conventional calcium L-channel blockers such as amlodipine in patients with CSFP. It was used in the second case as described above because calcium channel blockers are macro- and microvascular vasodilators used for slow flow during percutaneous coronary intervention (PCI). In one study regarding clinical and angiographic benefits of the calcium T-channel blocker mibefradil in CSFP patients, results showed reduction of total angina frequency by 56%, prolonged angina episodes > 20 minutes by 74%, and sublingual nitroglycerine consumption by 59% over a 12-month period. Angiographically, 13 out of 18 vessels showing TIMI-2 flow had abolition of the slow flow [25]. Currently, its use is limited due to occurrence of extensive drug interactions by inhibition of the cytochrome P450 3A4 pathway [26].


7. Syndrome X

An important differential to be considered in the diagnosis of CSFP is coronary syndrome X. Over the last few years, a number of important distinguishing features between these two seemingly similar entities have been identified (Table 2). In a study of 49 patients, Atak et al. documented increased QTc dispersion in patients with CSFP, which greatly increases the predisposition of sudden cardiac death due to malignant ventricular arrhythmias [27]. CSFP has also been termed as syndrome Y because of its interesting occurrence in syndrome X patients, after administration of neuropeptide Y [28].


8. Prognosis

The major long-term problem in CSFP patients is persistent and recurrent chest pain. One-third of these patients require readmission for an acute exacerbation [32]. In a study of 88 patients with angina and normal coronary arteries over a followup period of 6–11 years, chest pain diminished in 47%, and symptoms were unchanged in 24% or even worse in 29% of patients. However, 81% of patients with documented CSFP at coronary angiography reported chest pain to be similar or even worse than the initial episode [33].

Resting EKG abnormalities and positive exercise stress tests are more frequent in patients with CSFP. In one study of 53 patients with angina and angiographically normal epicardial coronary arteries and 40% having documented CSFP, 57% of patients had worsening or persistence of symptoms, and nonsignificant resting EKG abnormalities were seen in 27% while exercise-induced functional and perfusion abnormalities occurred in 69% of patients [34].

Patients with CSFP have a favorable long-term prognosis as reported by Lichtlen et al. in a prospective study of 176 patients with angina and normal coronary arteries. The median followup time period was 12.4 years. The rate of fatal myocardial infarction was found to be 0.05% per year, risk of death from coronary artery disease was 0.09% per year, and the rate of nonfatal myocardial infarction occurrence was 0.18% per year [35].


9. Conclusion

The major implications of this disease entity are reflected in the hampering of day-to-day life of CSFP patients with persistent chest pain and multiple hospital admissions. This is highlighted particularly well in the two cases presented here. There is a need for further extensive studies regarding the detailed pathogenesis and newer effective treatment modalities for this unique phenomenon with the potential to ameliorate the poor quality of life of patients with CSFP.


Conflict of Interests

There are no disclaimers or conflict of interests.


Ethical Approval

Informed consent has been obtained.


References
1. Tambe AA,Demany MA,Zimmerman HA,Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries—a new angiographic findingAmerican Heart JournalYear: 197284166715080284
2. Gibson CM,Cannon CP,Daley WL,et al. TIMI frame count: a quantitative method of assessing coronary artery flowCirculationYear: 19969358798888598078
3. Yilmaz H,Demir I,Uyar Z. Clinical and coronary angiographic characteristics of patients with coronary slow flowActa CardiologicaYear: 200863557958419014000
4. Azzarelli S,Grasso C,Galassi AR,Tamburino C. Coronary slow flow phenomenon: description of three cases evaluated with myocardial perfusion scintigraphyItalian Heart JournalYear: 20056434134415902934
5. Acikel S,Bozkaya OA,Akdemir R. The relationship between intermittent left bundle-branch block and slow coronary flow in a patient presenting with acute coronary syndromeBlood Coagulation and FibrinolysisYear: 201021659559720479640
6. Singh S,Kothari SS,Bahl VK. Coronary slow flow phenomenon: an angiographic curiosityIndian Heart JournalYear: 200456661361715751515
7. Diver DJ,Bier JD,Ferreira PE,et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA trial)American Journal of CardiologyYear: 19947465315378074033
8. Mosseri M,Yarom R,Gotsman MS,Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteriesCirculationYear: 19867459649723769180
9. Mangieri E,Macchiarelli G,Ciavolella M,et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteriesCatheterization and Cardiovascular DiagnosisYear: 19963743753818721694
10. Tanriverdi H,Evrengul H,Enli Y,et al. Effect of homocysteine-induced oxidative stress on endothelial function in coronary slow-flowCardiologyYear: 2007107431332017264512
11. Sezgin N,Barutcu I,Sezgin TA,et al. Plasma nitric oxide level and its role in slow coronary flow phenomenonInternational Heart JournalYear: 200546337338216043934
12. Selcuk MT,Selcuk H,Temizhan A,et al. Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flowCoronary Artery DiseaseYear: 200718754555117925608
13. Tanriverdi H,Evrengul H,Kilic ID,Taskoylu O,Dogan G,Alpsoy S. Aortic pressures, stiffness and left ventricular function in coronary slow flow phenomenonCardiologyYear: 2010116426126720798537
14. Beltrame JF,Limaye SB,Wuttke RD,Horowitz JD. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenonAmerican Heart JournalYear: 20031461849012851612
15. Turhan H,Erbay AR,Yasar AS,Bicer A,Sasmaz H,Yetkin E. Impaired coronary blood flow in patients with metabolic syndrome: documented by Thrombolysis in Myocardial Infarction (TIMI) frame count methodAmerican heart journalYear: 2004148578979415523308
16. Sharman JE,Moir S,Kostner KM,Haluska B,Marwick TH. Patients with coronary slow flow phenomenon demonstrate normal myocardial blood flow and arterial wave reflection between acute episodesInternational Journal of CardiologyYear: 2009131332132518582970
17. Turkmen M,Barutcu I,Esen AM,Karakaya O,Esen O,Basaran Y. Effect of slow coronary flow on P-wave duration and dispersionAngiologyYear: 200758440841217652223
18. Erdogan D,Caliskan M,Gullu H,Sezgin AT,Yildirir A,Muderrisoglu H. Coronary flow reserve is impaired in patients with slow coronary flowAtherosclerosisYear: 2007191116817416620834
19. Mangieri E,Tanzilli G,Vincentis GD,et al. Slow coronary flow and stress myocardial perfusion imaging. Different patterns in acute patientsJournal of Cardiovascular MedicineYear: 20067532232716645409
20. Cakmak M,Tanriverdi H,Cakmak N,Evrengul H,Cetemen S,Kuru O. Simvastatin may improve myocardial perfusion abnormality in slow coronary flowCardiologyYear: 20081101394417934268
21. Li JJ,Zheng X,Li J. Statins may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory propertyMedical HypothesesYear: 200769233333717215087
22. Fan Y,Lin JH,Dong G,Zhu J,Yin F,Yang SS. The effect of carvedilol on coronary flow reserve in patients with dilated cardiomyopathyZhonghua Nei Ke Za ZhiYear: 201049321721920450653
23. Tiryakioglu S,Tiryakioglu O,Ari H,et al. Effects of nebivolol on endothelial function and exercise parameters in patients with slow coronary flowClinical Medicine: CardiologyYear: 2009311511920508771
24. Kurtoglu N,Akcay A,Dindar I. Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flowAmerican Journal of CardiologyYear: 200187677777911249903
25. Beltrame JF,Turner SP,Leslie SL,Solomon P,Freedman SB,Horowitz JD. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenonJournal of the American College of CardiologyYear: 2004441576215234407
26. Becquemont L,Funck-Brentano C,Jaillon P. Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokineticsFundamental and Clinical PharmacologyYear: 199913223223610226769
27. Atak R,Turhan H,Sezgin AT,et al. Effects of slow coronary artery flow on QT interval duration and dispersionAnnals of Noninvasive ElectrocardiologyYear: 20038210711112848790
28. Kaski J,Tousoulis D,Rosano G,et al. Role of neuropeptide Y in the pathogenesis of syndrome XEuropean Heart JournalYear: 199213p. 103
29. Goel PK,Gupta SK,Agarwal A,Kapoor A. Slow coronary flow: a distinct angiographic subgroup in syndrome XAngiologyYear: 200152850751411512688
30. Saya S,Hennebry TA,Lozano P,Lazzara R,Schechter E. Coronary slow flow phenomenon and risk for sudden cardiac death due to ventricular arrhythmiasClinical CardiologyYear: 200831835235517957738
31. Fineschi M,Bravi A,Gori T. The “slow coronary flow” phenomenon: evidence of preserved coronary flow reserve despite increased resting microvascular resistancesInternational Journal of CardiologyYear: 2008127335836117651842
32. Beltrame JF,Limaye SB,Horowitz JD. The coronary slow flow phenomenon—a new coronary microvascular disorderCardiologyYear: 200297419720212145474
33. Voelker W,Euchner U,Dittmann H,Karsch KR. Long-term clinical course of patients with angina and angiographically normal coronary arteriesClinical CardiologyYear: 19911443073112032406
34. Ciavolella M,Avella A,Bellagamba S,Mangieri E,Nigri A,Reale A. Angina and normal epicardial coronary arteries: radionuclide features and pathophysiological implications at long-term follow-upCoronary Artery DiseaseYear: 1994564934997952408
35. Lichtlen PR,Bargheer K,Wenzlaff P. Long-term prognosis of patients with anginalike chest pain and normal coronary angiographic findingsJournal of the American College of CardiologyYear: 1995255101310187897110

Article Categories:
  • Review Article


Previous Document:  Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma Ap...
Next Document:  Association of Self-Reported Weight Change and Quality of Life, and Exercise and Weight Management B...